Physician profile
Devin Jorge Santiago
NPI 1821628561
$3,168.42
in general payments reported to CMS, 2019-2025
22 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,116 · 2022: $1,566 · 2023: $101 · 2024: $216 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.37 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $368.08 | 2021-2022 | |
| Lundbeck LLC | $334.44 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $224.52 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.01 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $177.58 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $169.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.23 | 2021-2022 | |
| Alpha Cognition USA, INC. | $143.94 | 2025 | Zunveyl |
| Tris Pharma INC | $104.94 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $94.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $89.54 | 2021-2022 | |
| Corium, LLC | $63.39 | 2022 | |
| Ironshore Pharmaceuticals INC. | $57.67 | 2022 | |
| Merck Sharp & Dohme LLC | $53.60 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.51 | 2024 | Cobenfy |
| Axsome Therapeutics, INC. | $24.22 | 2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $21.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.83 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $15.71 | 2021 | |
| Neos Therapeutics, LP | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Santiago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.